Seeks to exempt CGST on specified medicines used in COVID-19, up to 31st December, 2021
G.S.R….(E).- In exercise of the powers conferred by sub-section (1) of section 6 of the Integrated Goods and Services Tax Act, 2017 (13 of 2017) (hereafter in this notification referred to as “the said Act”), the Central Government, on being satisfied that it is necessary in the public interest so to do, on the recommendations of the Council, hereby exempts the goods specified in column (3) of the Table below, falling under the tariff item, sub-heading, heading or Chapter as specified in the First Schedule to the Customs Tariff Act, 1975 (51 of 1975), as the case may be, as specified in the corresponding entry in column (2) of the said Table, from so much of the integrated tax leviable thereon under section 5 of the said Act, as is in excess of the amount calculated at the rate as specified in corresponding entry in column (4) of the aforesaid Table, namely:-
Table
|
Sl. No. |
Chapter, Heading, Sub- heading or Tariff item |
Description of Goods |
Rate |
|
(1) |
(2) |
(3) |
(4) |
|
1 |
30 |
Tocilizumab |
Nil |
|
2 |
30 |
Amphotericin B |
Nil |
|
3 |
30 |
Remdesivir |
5% |
|
4 |
30 |
Heparin(anti-coagulant) |
5% |
|
5 |
30 |
Itolizumab |
5% |
|
6 |
30 |
Posaconazole, |
5% |
|
7 |
30 |
Infliximab |
5% |
|
8 |
30 |
Bamlanivimab&Etesevimab |
5% |
|
9 |
30 |
Casirivimab&Imdevimab |
5% |
|
10 |
30 |
2-Deoxy-D-Glucose |
5% |
|
11 |
30 |
Favipiravir |
5% |
2. This notification shall come into force on the 1stday of October, 2021.
Note: - The principal notification No. 40/2017-Integrated Tax (Rate), dated the 18th October, 2017, was published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R. 1311(E), dated the 18th October, 2017.
Related Documents :
12/2021-ITR